ACI’s Clinical Drug Safety Conference February 6-7 2008 London, UK
ACI’s Clinical Drug Safety Conference will address the challenges in monitoring and maintaining drug safety strategies throughout clinical trials. Understand how to apply innovative strategic approaches to effectively manage clinical safety; discover key developments in the handling, analysis and reporting of adverse events during trials and understand the regulators requirements with the aim of speeding drugs to market whilst mitigating the risk of recall.
The programme will focus on key topics including:
· Implementing a progressive pharmacovigilance strategy
· Key technological advances to support effective management of clinical safety issues during development
· Effective handling and analysis of adverse event data – best practices for capturing and reporting safety data
· Reducing risk earlier to mitigate the threat of post-marketing recall
· Meeting the regulator’s safety requirements
The expert panel of speakers comprises principal decision-makers and researchers from leading pharmaceutical and biotech companies, giving you an insight into the latest developments in drug safety strategy and research within clinical trials, through key industry case study presentations.
Among the speakers:
· Dr. Lisbeth Tofte Hemmingsen, Group Director, International Clinical Quality Assurance, Nycomed Group
· Dr. Hans Mosberg, Director Medical Safety Strategy, Nycomed GmbH
· Dr. Bledar Haderi, Drug Safety & Epidemiology Manager, AstraZeneca
· Dr. Jill Robinson, Vice President, Global Pharmacovigilance Operations , Wyeth
· Dr. Thomas Stoehr, Scientific Leader, Pharmacology, Schwarz BioSciences
· Dr. Nilima Justice, Senior Director, Product Safety Surveillance, Novo Nordisk
· Dr. Valerie Shaw, Director and Product Safety Risk Management Lead, Pfizer
· Dr. William Maier, Director of Epidemiology, Elan Pharmaceuticals Ltd
Who will attend?
Attendees will be drawn primarily from pharmaceutical, biotechnology and contract research organisations and include VPs, Directors and Managers/Scientists working in Drug Safety, Toxicology, Pharmacology, Pharmacovigilance, Epidemiology, Clinical Research and Development, Clinical Trial Management, Regulatory Affairs and Compliance, Strategy and Business Development.
Information & Registration
The program is written by end-users for end-users. That means that you will be attending with only 80 to 100 of your peers from the Global Pharmaceutical and Biotech Industry and will not be surrounded by suppliers trying to sell their products. The success of our conferences is based on a limited number of delegate spaces and a very restricted group of targeted vendors.
To book or to get additional information on the conference, please contact Melanie Mulazzi of ACI on +44 20 7981 2504 or email her at mmulazzi@acius.net.
www.acius.net
